Searching for your content…
from 8 AM – 10 PM ET
News provided by
Mar 08, 2022, 02:00 ET
Share this article
NEW YORK, March 8, 2022 /PRNewswire/ — The non-small cell lung cancer drugs market will be driven by factors such as increasing prevalence and incidence of non-small cell lung cancer. The market is expected to grow by USD 30.23 bn from 2021 to 2026, progressing at a CAGR of 17.1% during the forecast period, according to Technavio. The report offers an up-to-date analysis as well as exact growth variance and the Y-O-Y growth rate.
Find additional highlights related to the market. Request a Free Sample Report.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Scope
The non-small cell lung cancer drugs market report covers the following areas:
Non-small Cell Lung Cancer Drugs Market 2022-2026: Segmentation
By product, the market has been segmented into biologics, small molecule targeted therapy, and chemotherapy. The biologics segment will have significant market share growth during the forecast period. The growth of the market is driven by the increased prevalence of non-small cell lung cancer and the availability of biologics to treat the disease.
By geography, the market has been segmented into North America, Europe, Asia, and Rest Of World (ROW). North America will have the highest market share growth during the forecast period.
Learn about the contribution of each segment of the market. Download a Free Sample
Non-small Cell Lung Cancer Drugs Market 2022-2026: Drivers and Challenges
The increasing prevalence and incidence of non-small cell lung cancer is driving the non-small cell lung cancer drugs market growth. This is due to the rise in risk factors such as cigarette smoking, secondary smoking, air pollution, and occupational exposure. In Asian countries, rapid industrial development and sub-urbanization, and disease patterns are leading to the increased prevalence of non-small cell lung cancer.
Factors such as high cost of treatment may challenge the market growth. Non-small cell lung cancer can be treated by surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy. However, the cost of these treatments is very high. Immunotherapy for non small cell lung cancer may include immune checkpoint inhibitors such as OPDIVO, KEYTRUDA, TECENTRIQ, and IMFINZI. The overall cost of treatment, including diagnosis, hospitalization, outpatient office visits, and a monthly initial treatment phase, is USD 46,000 per patient.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Vendor Analysis
We provide a detailed analysis of around 25 vendors operating in the Non-small Cell Lung Cancer Drugs Market, including AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd. among others.
Subscribe to our "Lite Plan" billed annually at USD 3000 that enables you to download 3 reports/year and view 3 reports/month.
Non-small Cell Lung Cancer Drugs Market 2022-2026: Key Highlights
Janus Kinase (JAK) Inhibitors Market by Application and Geography – Forecast and Analysis 2022-2026
Myocardial Infarction (MI) Therapeutics Market by Product and Geography – Forecast and Analysis 2022-2026
Non-small Cell Lung Cancer Drugs Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of 17.1%
Market growth 2022-2026
USD 30.23 billion
YoY growth (%)
North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution
North America at 39%
Key consumer countries
US, Canada, Germany, UK, and China
Leading companies, competitive strategies, consumer engagement scope
AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, BeiGene Ltd., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Innovent Biologics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Merck and Co. Inc., Merck KGaA, Novartis AG, Ono Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, and Takeda Pharmaceutical Co. Ltd.
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table Of Contents :
Five Forces Analysis
Market Segmentation by Product
Drivers, Challenges, and Trends
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
More news releases in similar topics
Cision Distribution 888-776-0942
from 8 AM – 9 PM ET